Skip to main content
Drug Development
Our Pipeline
Evaluation Pipeline
Therapeutic areas
Partnering
Useful Links
News
Investors
Regulatory News
AIM Rule 26
Annual and Half Yearly Reports
Admission Document & Articles
Shareholder communications
Investments Calculator
Share Alerts
Share Series
Share price look-up
Analyst Research
About us
Board of Directors and Management Team
Strategy and Vision
How we work
Working with us
Collaborative Pipeline
Contact us
Search
News
Breadcrumb
News
Category
Articles
Events and presentations
News
Press releases
Videos and audiocasts
News
ValiRx signs IP license agreement with King's College London to progress triple negative breast cancer treatment
24 Oct 2022
News
ValiRx appoints NED to support growth and investment drive
19 Oct 2022
Articles
Ada Lovelace Day 2022: In conversation with ValiRx’s CEO
11 Oct 2022
Videos and audiocasts
ValiRx Q&A Live Webinar Held on 29th September 2022
29 Sep 2022
News
ValiRx bolsters drug discovery expertise with key appointment
23 Sep 2022
Videos and audiocasts
Successful evaluation of triple negative breast cancer programme
15 Jul 2022
Events and presentations
AGM & Live Q&A with Presentation Held on 30th June 2022
1 Jul 2022
Videos and audiocasts
Live Q&A Webinar With Presentation Held on 6th April 2022
6 Apr 2022
Articles
ValiRx Recognised in the Biotechnology Awards 2022
5 Apr 2022
Videos and audiocasts
ValiRx update on proposed sub-license of VAL201
23 Mar 2022
Videos and audiocasts
Growth & Innovation Forum Presentation 2022
11 Feb 2022
Videos and audiocasts
ValiRx Signs Agreement with TheoremRX
5 Jan 2022
Videos and audiocasts
ValiRx Amends License for VAL201 with Cancer Research Technology
20 Dec 2021
Videos and audiocasts
ValiRx CEO, Dr Suzanne Dilly Presents at the LSE Investor Webinar
8 Dec 2021
Pagination
First page
First
Previous page
Previous
Page
1
Current page
2
Page
3
Page
4
Next page
Next
Last page
Last
